Consequently, the combination of PD-1 antibodies with CAR-NK-cell therapy emerges as a potential strategy to reverse tumour escape pathways, reverse CAR-NK-cell exhaustion, and enhance their efficacy [148]. This evidence concerns the gene PDCD1 and neoplasm.